@FiercePharma: Eisai to shave 900 from payroll over five years. Report | Follow @FiercePharma
> A Connecticut law firm has filed a lawsuit against Merck on behalf of men who have taken Propecia, a prescription drug that combats hair loss but, its critics say, can also cause severe side effects such as sexual dysfunction and mental impairment. Article
> As Indian and European Union (EU) trade officials meet in Brussels for further sessions of their long-running Free Trade Agreement negotiations, thousands have protested against the deal's plans for generic drugs. Story
> AstraZeneca and Bristol-Myers Squibb say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment. Report
> Options activity was heavy in the pharmaceutical sector as bulls and bears diverged over the prospects for Pfizer, Bristol-Myers Squibb and Amylin Pharmaceuticals. Report
> Goldman Sachs said investors should buy Bristol-Myers Squibb calls as approval for a melanoma treatment may boost the drugmaker's stock price. Item
> Valeant Pharmaceuticals sold $1.5 billion senior notes in two parts in the 144a private placement market, said IFR, a Thomson Reuters service. Article
> A group of drugmakers have sued Mylan over its attempt to gain FDA approval for a generic menopause drug, the company said. News
> A federal judge in Florida stayed his own ruling against the Obama health care law on Thursday, allowing the act to be carried out as the case progresses through the Courts of Appeal and on to the Supreme Court. Item
Biotech News
@FierceBiotech: FierceBiotech's Clinical Trials Executive Breakfast series heads to San Francisco. Article | Follow @FierceBiotech
@JohnCFierce: Here's the PR on tofacitinib, which is probably the best late-stage prospect Pfizer has now. Don't get name change. Item | Follow @JohnCFierce
> GSK cancels $1.5B Targacept pact. Report
> Pfizer's blockbuster RA hopeful clears a Ph3 hurdle. News
> Survey: Happiness is found in biotech jobs. Story
> Biotechs join forces in TB-fighting consortium. Item
> FDA staffers question higher dose of Novartis' indacaterol. Article
> Ex-Lilly neuroscience chief headed to J&J. Report
And Finally... The ghosts of mass torts past have been popping up all over the place. Story